Edoxaban vs. Warfarin in Vitamin K antagonist experienced and naive patients with atrial fibrillation

European Heart Journal

Volumn 36, Issue 23, 2015, Pages 1470-1477

  O'Donoghue, Michelle L ^a   Ruff, Christian T ^a   Giugliano, Robert P ^a   Murphy, Sabina A ^a   Grip, Laura T ^a   Mercuri, Michele F ^b   Rutman, Howard ^b   Shi, Minggao ^b   Kania, Grzegorz ^c   Cermak, Ondrej ^d   Braunwald, Eugene ^a   Antman, Elliott M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DAIICHI SANKYO INC   (United States)

^c Centrum Medyczne 'Ogrodowa'   (Poland)

^d Slany Municipal Hospital   (Czech Republic)

Author keywords

Atrial fibrillation; Edoxaban; Novel oral anticoagulant; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BODY MASS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTEMIC EMBOLIC EVENT; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; RISK FACTORS; STROKE; THIAZOLES; TREATMENT OUTCOME; WARFARIN;

EID: 84933586067     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv014     Document Type: Article

References (13)

1. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104.
2. Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, Karasoy D, Lamberts M, Charlot M, Kober L, Weeke P, Lip GY, Hansen ML. Dabigatran use in Danish atrial fibrillation patients in 2011: A nationwide study. BMJ Open 2013; 3: doi: 10.1136/bmjopen-2013-002758.
3. Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, Spettell CM, Brennan TA, Matlin OS, Avorn J, Choudhry NK. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation - quality and cost implications. Am J Med 2014;127:1075-1082.
4. Hylek EM, Frison L, Henault LE, Cupples A. Disparate strokerateson warfarinamong contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke 2008;39:3009-3014.
5. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
6. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-641.
7. EzekowitzMD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S. Dabigatran and warfarin in vitamin K antagonistnaive and -experienced cohorts with atrial fibrillation. Circulation 2010;122: 2246-2253.
8. Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J 2013;166: 549-558.
9. Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KA, Breithardt G, Hacke W. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: A subgroup analysis of a randomized trial. Ann Intern Med 2013;158:861-868.
10. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006;367:1903-1912.
11. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029-2037.
12. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E.Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007;370:493-503.
13. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, AlbersGW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 2007;167:239-245.